Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FP-01.1 + placebo
- Development stage
- Unknown
- Lead developer
- Altimmune
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular (based On Standard Administration For Peptide Vaccines)
01
Overview
FP-01.1 + placebo refers to the combination of the investigational vaccine FP-01.1 and a matching placebo as used in randomized controlled clinical trials for influenza A prevention and immunogenicity studies. FP-01.1 is a novel synthetic peptide-based pan-influenza A vaccine composed of six fluorocarbon-modified 35-mer peptides that encapsulate multiple CD4+ and CD8+ T-cell epitopes from influenza A virus proteins, designed to induce broad cellular immune responses across diverse populations[2][3][5]. The mechanism involves stimulating both CD4+ and CD8+ T cell responses, leading to robust anti-viral immunity with cross-recognition of divergent influenza strains[2]. Placebo is an inert substance used as a control in these studies.
- Brand names
- Flunisyn
02
Targets
MHC I (MHC class I})MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on FP-01.1 + placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FP-01.1 + placebo.